<p>美国主要股指近期因就业数据延迟而回落，失业率高于预期。在这种情况下，投资于便士股票——这一投资领域尽管有些过时，但仍然具有相关性——仍然可以提供独特的机会。这些股票通常代表较小或较新的公司，当其财务状况良好时，可以提供价格实惠和增长潜力的结合。让我们来看看几只因财务实力而脱颖而出的有前景的便士股票。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器的 342 只股票的完整列表。</p>
<p>让我们回顾一些我们筛选出的显著股票。</p>
<h2>Cumberland Pharmaceuticals (CPIX)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Cumberland Pharmaceuticals Inc. 是一家专注于医院急救、胃肠病学和肿瘤学的专科制药公司，在美国和国际上收购、开发和商业化处方产品，市值为 4442 万美元。</p>
<p><strong>运营：</strong> 公司的收入完全来自其专科制药产品，总计 4128 万美元。</p>
<p><strong>市值：</strong> $44.42M</p>
<p>Cumberland Pharmaceuticals Inc. 的市值为 4442 万美元，交易价格低于其估计公允价值的 58.4%，这表明在便士股票领域对投资者具有潜在价值。尽管处于亏损状态，Cumberland 在过去五年中减少了损失，并保持超过三年的正现金流。最近的发展包括与战略合作伙伴关系共同商业化 Talicia，并扩大 Vibativ 在沙特阿拉伯的市场覆盖，同时为 Caldolor®注射液获得 CMS 报销——这是一种在持续的阿片类药物危机中提供的非阿片类疼痛管理选择，突显了其多元化收入来源和增强财务稳定性的努力。</p>
<ul>
<li>点击这里深入了解 Cumberland Pharmaceuticals 的具体情况，查看我们的详细资产负债表健康报告。</li>
<li>通过访问我们的历史表现报告，评估 Cumberland Pharmaceuticals 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis"/></p>
<p>CPIX 负债与股本历史及分析截至 2025 年 12 月</p>
<h2>American Well (AMWL)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> American Well Corporation 是一家企业平台和软件公司，提供数字化混合护理服务，业务遍及美国和国际，市值约为 7547 万美元。</p>
<p><strong>运营：</strong> 公司的收入来自其互联网信息提供商部门，总计为 2.6502 亿美元。</p>
<p><strong>市值：</strong> $75.47M</p>
<p>American Well Corporation 的市值为 7547 万美元，运营于数字医疗领域，面临便士股票典型的挑战，如亏损和-42.78% 的负股本回报率。尽管如此，它仍保持强劲的财务状况，短期资产为 2.712 亿美元，远超其短期和长期负债。公司没有债务，现金流足以支持超过三年的运营，如果当前现金流趋势持续。最近的指导修订表明，预计 2025 年的收入将在 2.45 亿到 2.48 亿美元之间稳定，尽管正在进行运营调整。</p>
<ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 American Well 的动态。</li>
<li>通过查看我们的增长报告，获取对 American Well 未来方向的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis"/></p>
<p>AMWL 财务状况分析截至 2025 年 12 月</p>
<h2>Liquidmetal Technologies (LQMT)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Liquidmetal Technologies, Inc. 是一家材料技术公司，设计、开发和销售由大宗非晶合金制成的定制产品和零部件，服务于全球各个行业，市值为 9631 万美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自开发和制造使用非晶合金的产品和应用，总计为 74 万美元。</p>
<p><strong>市值：</strong> $96.31M</p>
<p>Liquidmetal Technologies, Inc. 的市值为 9631 万美元，仍处于无收入状态，收益仅为 74 万美元。尽管处于亏损状态，但在过去五年中每年减少损失 13.6%，并保持良好的财务基础，没有债务，短期资产为 1490 万美元，远超负债。公司报告 2025 年第三季度收入下降至 3.7 万美元，较去年同期下降，而净亏损扩大至 55.2 万美元，反映出在其专注于非晶合金开发的战略中实现盈利的持续挑战。</p>
<ul>
<li>点击这里了解 Liquidmetal Technologies 的细微差别，查看我们的详细分析财务健康报告。</li>
<li>通过查看我们的历史业绩报告，深入了解 Liquidmetal Technologies 的历史成果。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 12 月 LQMT 的债务与股本历史及分析</p>
<h2>总结</h2>
<ul>
<li>解锁更多宝藏！我们的美国便士股票筛选器为您挖掘了 339 家更多公司供您探索。点击这里揭开我们精心策划的 342 家美国便士股票的名单。</li>
<li>寻找替代机会？我们发现 13 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单，免费获取。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的全自动塔。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

AMWL

<p>新闻强调了 Cumberland Pharmaceuticals 作为近期美国经济形势下的领先低价股。尽管该公司尚未盈利，但其市值为 4442 万美元，交易价格低于其估计的公允价值，显示出潜力。公司在五年内减少了亏损，保持了正现金流，并通过战略合作伙伴关系扩大市场覆盖。报告还提到其他有前景的低价股，如 American Well 和 Liquidmetal Technologies，强调了它们的财务健康和增长潜力</p>

<p>Major stock indexes in the United States have recently retreated following delayed jobs data, with unemployment rates higher than anticipated. In this context, investing in penny stocks—an investment area that remains relevant despite being somewhat outdated—can still present unique opportunities. These stocks often represent smaller or newer companies and can offer a blend of affordability and growth potential when backed by strong financials. Let's examine several promising penny stocks that stand out for their financial strength.</p>
<div class="lb-trans"><p>美国主要股指近期因就业数据延迟而回落，失业率高于预期。在这种情况下，投资于便士股票——这一投资领域尽管有些过时，但仍然具有相关性——仍然可以提供独特的机会。这些股票通常代表较小或较新的公司，当其财务状况良好时，可以提供价格实惠和增长潜力的结合。让我们来看看几只因财务实力而脱颖而出的有前景的便士股票。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.05</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.05</td>
<td>$179.57M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.16</td>
<td>$531.71M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Perfect (PERF)</td>
<td>$1.76</td>
<td>$178.24M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$4.97</td>
<td>$56.35M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$589.37M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8701</td>
<td>$6.32M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.05</td>
<td>$91.76M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 342 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器的 342 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>让我们回顾一些我们筛选出的显著股票。</p>
</div><h2>Cumberland Pharmaceuticals (CPIX)</h2>
<div class="lb-trans"><h2>Cumberland Pharmaceuticals (CPIX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and commercializes prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally, with a market cap of $44.42 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cumberland Pharmaceuticals Inc. 是一家专注于医院急救、胃肠病学和肿瘤学的专科制药公司，在美国和国际上收购、开发和商业化处方产品，市值为 4442 万美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived entirely from its specialty pharmaceutical products, totaling $41.28 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入完全来自其专科制药产品，总计 4128 万美元。</p>
</div><p><strong>Market Cap:</strong> $44.42M</p>
<div class="lb-trans"><p><strong>市值：</strong> $44.42M</p>
</div><p>Cumberland Pharmaceuticals Inc., with a market cap of US$44.42 million, has been trading at 58.4% below its estimated fair value, indicating potential value for investors in the penny stock space. Despite being unprofitable, Cumberland has reduced its losses over the past five years and maintains a positive cash flow runway exceeding three years. Recent developments include strategic partnerships to commercialize Talicia and expand Vibativ's market reach in Saudi Arabia, alongside securing CMS reimbursement for Caldolor® Injection—a non-opioid pain management option amid an ongoing opioid crisis—highlighting efforts to diversify revenue streams and enhance financial stability.</p>
<div class="lb-trans"><p>Cumberland Pharmaceuticals Inc. 的市值为 4442 万美元，交易价格低于其估计公允价值的 58.4%，这表明在便士股票领域对投资者具有潜在价值。尽管处于亏损状态，Cumberland 在过去五年中减少了损失，并保持超过三年的正现金流。最近的发展包括与战略合作伙伴关系共同商业化 Talicia，并扩大 Vibativ 在沙特阿拉伯的市场覆盖，同时为 Caldolor®注射液获得 CMS 报销——这是一种在持续的阿片类药物危机中提供的非阿片类疼痛管理选择，突显了其多元化收入来源和增强财务稳定性的努力。</p>
</div><ul>
<li>Dive into the specifics of Cumberland Pharmaceuticals here with our thorough balance sheet health report.</li>
<li>Evaluate Cumberland Pharmaceuticals' historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Cumberland Pharmaceuticals 的具体情况，查看我们的详细资产负债表健康报告。</li>
<li>通过访问我们的历史表现报告，评估 Cumberland Pharmaceuticals 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/1c609fa3-4864-418d-8077-1b5fffaa7db6/chart/debt-equity-history-analysis"/></p>
<p>CPIX Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>CPIX 负债与股本历史及分析截至 2025 年 12 月</p>
</div><h2>American Well (AMWL)</h2>
<div class="lb-trans"><h2>American Well (AMWL)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> American Well Corporation is an enterprise platform and software company that provides digitally enabled hybrid care services in the United States and internationally, with a market cap of approximately $75.47 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> American Well Corporation 是一家企业平台和软件公司，提供数字化混合护理服务，业务遍及美国和国际，市值约为 7547 万美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Internet Information Providers segment, which amounted to $265.02 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入来自其互联网信息提供商部门，总计为 2.6502 亿美元。</p>
</div><p><strong>Market Cap:</strong> $75.47M</p>
<div class="lb-trans"><p><strong>市值：</strong> $75.47M</p>
</div><p>American Well Corporation, with a market cap of US$75.47 million, operates in the digital healthcare sector and faces challenges typical of penny stocks, such as unprofitability and negative return on equity at -42.78%. Despite this, it maintains a strong financial position with short-term assets of US$271.2 million well exceeding both its short- and long-term liabilities. The company has no debt and possesses a cash runway sufficient for over three years if current cash flow trends persist. Recent guidance revisions suggest revenue stabilization between US$245 million to US$248 million for 2025 amidst ongoing operational adjustments.</p>
<div class="lb-trans"><p>American Well Corporation 的市值为 7547 万美元，运营于数字医疗领域，面临便士股票典型的挑战，如亏损和-42.78% 的负股本回报率。尽管如此，它仍保持强劲的财务状况，短期资产为 2.712 亿美元，远超其短期和长期负债。公司没有债务，现金流足以支持超过三年的运营，如果当前现金流趋势持续。最近的指导修订表明，预计 2025 年的收入将在 2.45 亿到 2.48 亿美元之间稳定，尽管正在进行运营调整。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of American Well.</li>
<li>Gain insights into American Well's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 American Well 的动态。</li>
<li>通过查看我们的增长报告，获取对 American Well 未来方向的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/91e959b8-d4f4-4dd3-ac2f-fcc215c0ed18/chart/financial-position-analysis"/></p>
<p>AMWL Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>AMWL 财务状况分析截至 2025 年 12 月</p>
</div><h2>Liquidmetal Technologies (LQMT)</h2>
<div class="lb-trans"><h2>Liquidmetal Technologies (LQMT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Liquidmetal Technologies, Inc. is a materials technology company that designs, develops, and sells custom products and parts made from bulk amorphous alloys to various industries globally, with a market cap of $96.31 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Liquidmetal Technologies, Inc. 是一家材料技术公司，设计、开发和销售由大宗非晶合金制成的定制产品和零部件，服务于全球各个行业，市值为 9631 万美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from developing and manufacturing products and applications using amorphous alloys, totaling $0.74 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自开发和制造使用非晶合金的产品和应用，总计为 74 万美元。</p>
</div><p><strong>Market Cap:</strong> $96.31M</p>
<div class="lb-trans"><p><strong>市值：</strong> $96.31M</p>
</div><p>Liquidmetal Technologies, Inc., with a market cap of US$96.31 million, remains pre-revenue with earnings of just US$0.74 million. Despite being unprofitable, it has reduced losses by 13.6% annually over the past five years and maintains a solid financial footing with no debt and short-term assets of US$14.9 million surpassing liabilities significantly. The company reported declining revenues for Q3 2025 at US$0.037 million compared to the previous year while net losses widened to US$0.552 million from US$0.441 million, reflecting ongoing challenges in achieving profitability amidst its strategic focus on amorphous alloys development.</p>
<div class="lb-trans"><p>Liquidmetal Technologies, Inc. 的市值为 9631 万美元，仍处于无收入状态，收益仅为 74 万美元。尽管处于亏损状态，但在过去五年中每年减少损失 13.6%，并保持良好的财务基础，没有债务，短期资产为 1490 万美元，远超负债。公司报告 2025 年第三季度收入下降至 3.7 万美元，较去年同期下降，而净亏损扩大至 55.2 万美元，反映出在其专注于非晶合金开发的战略中实现盈利的持续挑战。</p>
</div><ul>
<li>Click here to discover the nuances of Liquidmetal Technologies with our detailed analytical financial health report.</li>
<li>Gain insights into Liquidmetal Technologies' historical outcomes by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解 Liquidmetal Technologies 的细微差别，查看我们的详细分析财务健康报告。</li>
<li>通过查看我们的历史业绩报告，深入了解 Liquidmetal Technologies 的历史成果。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/051b8377-1d31-4b53-bdb2-47b5eb5301b5/chart/debt-equity-history-analysis"/></p>
<p>LQMT Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月 LQMT 的债务与股本历史及分析</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Unlock more gems! Our US Penny Stocks screener has unearthed 339 more companies for you to explore.Click here to unveil our expertly curated list of 342 US Penny Stocks.</li>
<li>Looking For Alternative Opportunities? We've found 13 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁更多宝藏！我们的美国便士股票筛选器为您挖掘了 339 家更多公司供您探索。点击这里揭开我们精心策划的 342 家美国便士股票的名单。</li>
<li>寻找替代机会？我们发现 13 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单，免费获取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的全自动塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

坎伯兰制药引领 3 只有潜力的便士股